The EBMT’s Post

⚡ Nivolumab plus platinum-doubletchemotherapy in treatment-naive patientswith advanced grade 3 NeuroendocrineNeoplasms of gastroenteropancreatic orunknown origin: The multicenter phase 2NICE-NEC trial (GETNE-T1913) 🦓 #NeuroendocrineTumors https://buff.ly/46MiN8T

Last week, BiomX announced the completion of patient enrollment for our Phase 1b/2a study of BX211 in patients with DFO (diabetic foot osteomyelitis). ✨ This milestone marks significant progress in advancing phage therapy as a transformative approach to unmet medical needs. 📊 Stay tuned – results from this trial are on track to be reported in the coming quarter! 🔗 Learn more about BX211: https://bit.ly/4eNfSiT #BiomX #clinicaltrial #DFO #bacteriophage #unmetneeds #phagetherapy

Vicore Pharma AB is pleased to announce positive final results from the Phase 2a AIR trial demonstrating that buloxibutid improves lung function over 36 weeks in patients with idiopathic pulmonary fibrosis (#IPF). These encouraging results were presented yesterday by Toby Maher, Keck School of Medicine of USC, as a late-breaking oral session at the American Thoracic Society International Congress (#ATS2024). Vicore will be discussing the results in more detail during a webinar on Wednesday 5/22 at 10:00 ET/16:00 CET. You can register for the webinar here: https://lnkd.in/eKp8xYGj #pulmonaryfibrosis #biotechnews #respiratory #clinicaldata

We're so pleased to report positive final results for Vicore Pharma AB's AT2 receptor agonist, buloxibutid, in the Phase 2a AIR study in IPF, reflecting disease-modifying potential. We believe that agonizing an upstream pathway impacting precursor alveolar epithelial type II cells is a excellent approach to this tough disease and are looking forward to initiating the Phase 2b ASPIRE study to advance this exciting molecule! #ATS2024 #IPF #PulmonaryFibrosis

We are collaborating with Thermo Fisher Scientific on obtaining FDA approval for One Lambda™ Devyser Accept cfDNA 🤝, our co-branded NGS solution for detecting donor-derived cell-free DNA (ddcfDNA) in blood samples from kidney-transplanted patients. This collaboration has the promise to improve U.S. post-transplant monitoring with the introduction of widely available non-invasive methods. As our CEO Fredrik Alpsten notes, “Securing FDA-approval for One Lambda Devyser Accept cfDNA has the potential to change how kidney transplant monitoring is done in the United States.” Once approved, this will be our first post-transplant monitoring product available in the U.S. market— a transformative step for kidney transplant care. Together, we're committed to bringing improved care options for the 150,000+ Americans living with a kidney transplant.💙 Read the Press Release here: https://lnkd.in/dGGVzk-g #Devyser #ThermoFisher #KidneyTransplant #TransplantCare #NGS #FDAApproval #HealthcareInnovation #cfDNA #TransplantMonitoring #MedicalAdvancements #USHealthcare

Not long to go until the PROMs Research Conference! Get in touch at https://bit.ly/4aPkmTV to arrange a chat with our team. We will be presenting the following posters at the event: Poster 1: Patient-reported outcome measures used in interventional studies of irritable bowel syndrome: a targeted review Poster 2: Outcomes and interventions in clinical studies investigating pharmacological therapies for the treatment of transthyretin amyloidosis: a targeted review https://bit.ly/4cb2sML

Physiomics plc is proud to collaborate with Beyond Blood Diagnostics and Blackpool Teaching Hospitals NHS Foundation Trust on an innovative project aimed at developing a personalised dosing tool for patients undergoing chemotherapy with docetaxel. Neutropenia, where patients have an abnormally low count of neutrophils, is a common and serious side effect of chemotherapy. It increases the risk of infections, and managing it effectively is crucial to avoid treatment delays. 💡 Through advanced mathematical modelling and data analysis techniques, we aim to develop a robust clinical decision support system that can help clinicians predict the risk of neutropenia for individual patients and guide the optimal dosing of G-CSF, a medication that stimulates neutrophil production. At Physiomics plc, we are committed to advancing #precisionmedicine through innovative solutions, ensuring every patient receives the best possible care based on their needs. Learn more 👇 https://lnkd.in/eQDtKjJX #personaliseddosing #chemotherapy #cancertreatment #precisionmedicine #ukinnovation

🚨 In the News 🚨 We’re excited to see Imbed Biosciences featured for their groundbreaking achievement! On October 31st, the FDA approved Microlyte Ag/Lidocaine, the first-ever antimicrobial wound dressing that combines lidocaine with silver for antimicrobial control. This innovative dressing brings dual benefits: providing antimicrobial protection and local anesthetic effects, ideal for managing painful wounds. Read the full mention on this in the article below, as Imbed Biosciences continues to lead the way in advanced wound care. 📖 #InTheNews #HealthcareInnovation #WoundCare #FDAApproval #PainManagement #ImbedBiosciences #MedicalBreakthrough

Congratulations to the entire team at Bitterroot Bio on the successful launch / dosing of first participants in a Phase I clinical trial for BRB-002! This pioneering study represents a significant step forward in the battle against atherosclerotic cardiovascular disease (ASCVD), a leading cause of mortality worldwide. 🔬 BRB-002 is not just another treatment; it's a novel protein therapy targeting CD47 with the potential to transform the cardiovascular health landscape. The dedication of the Bitterroot team to addressing unmet needs in cardio-immunology shines through this achievement. 💉 Dosing the first human participants marks a pivotal transition for Bitterroot into a clinical-stage company. This progress is a testament to the hard work and perseverance of the team, led by Craig Basson, MD, PhD, Chief Medical Officer. 👏 Here's to hoping that BRB-002 will bring new hope to patients and set new standards in cardiovascular care. Keep pushing the boundaries, Bitterroot Bio! #CardiovascularHealth #Innovation #ClinicalTrials #BitterrootBio #HealthcareInnovation #Biotech #Phase1 #ASCVD #Congratulations #lifescience

Exciting news! Our abstract on the MosaiQ AiPlex® CD prototype has been published in the American Journal of Gastroenterology. This is a major step forward in advancing autoimmune diagnostics. Discover how we're pushing the boundaries of innovation. https://bit.ly/4flpG4N